Replies to post #170245 on Biotech Values

[DewDiligence]

Any chance JNJ ends up losing on this transaction? Just can't see much life left in Incivek.

JNJ presumably knows that the HCV market outside the US—especially in the Big-5 EU countries—has enough inertia to allow the $152M to be recouped. Additionally, the deal may have an element of tax arbitrage by increasing JNJ's foreign income and lowering its US income.